ARRAYJET SECURES CONTRACT FROM SHANGHAI-BASED ANTIBODY BIOMARKER COMPANY

 

arrayjet

ARRAYJET SECURES USD 300,000 CONTRACT FROM SHANGHAI-BASED ANTIBODY BIOMARKER COMPANY

 

  • Contract secured with Abmart consolidates Arrayjet’s continual growth in Asia Pacific
  • Abmart is a life science organisation which specialises in producing and developing monoclonal antibodies –a protein produced by immune system and used to identify and neutralize pathogens such as bacteria and viruses

 

Edinburgh, Scotland UK, Monday 5th December 2016; Arrayjet, a Scottish-based microarray instrumentation company, has secured a contract with Shanghai-based Abmart, a biological and life science technology specialist which is working to industrialise the production of monoclonal antibodies for academic research institutes, biotechnology companies and pharmaceutical laboratories across the globe.

 

Monoclonal antibodies are antibodies that are made by identical immune cells that are all clones of a unique parent cell, in contrast to polyclonal antibodies, which are made by several different immune cells. Different monoclonal antibodies recognise different proteins with high affinity and specificity. Therefore, monoclonal antibodies can be used in multiple applications, including, but not limited to, biological research, disease prevention, diagnosis, and therapeutics.

 

Each monoclonal antibody cost a considerable amount of time and money to develop using traditional industrial method. Abmart has already decreased the cost of monoclonal antibody development at a small fraction of traditional method. And yet, they have set an ambitious plan to push the cost further down through building standardized assembly lines to realize “monoclonal antibody democracy”: to enable at-will and on-demand monoclonal antibody development for any structural molecules in nature.

 

Abmart has accumulated a library of 100,000 different monoclonal antibodies against diverse antigens from numerous species, the capacity of which is still growing. A dedicated team of scientists of the company is focusing on the development of different applications of the antibody library. This is being done by considerable investment in technology innovation and systems engineering, with Arrayjet being pivotal to this process.

 

Abmart will use Arrayjet’s Super Marathon Microarrayer to print the 100,000 antibodies on to two small microarray chips, called MabArrayTM. In this way, any kind of protein samples of interest can be screened and analyzed by this enormous antibody library in just a small amount, which allows users to discover new disease biomarkers, novel drug targets, and even new cancer immunotherapy cheaply, easily and quickly.

 

Furthermore, MabArrayTM will also find broad applications in agricultural sciences for discovering critical proteins involving in economic plant and animal stock traits. These antibody library and microarrays can be used as powerful tools in both basic research and clinical and greatly help the development of the ‘holy grail’ of medical science – the personalized disease treatment.

 

Dr. Zhaohui Wang, Senior R&D manager of Abmart explains, partnerships, such as this one with Arrayjet is vital for its continued success. Dr. Wang further commented; “The reason we chose Arrayjet Super Marathon for production is that we are impressed by its high throughput, superior stability and consistency of printing performance. We have had issues with ‘repeatability’ in and between batches on our previous arrayer, so we are looking forward to a satisfying result from our Super Marathon and applying our competitive technology onto microarrays. This will minimize the reaction and produce easy-to-use screening tools for researchers so that they can do screening on their own.”

 

For Arrayjet, Iain McWilliam, CEO commented; “There is a great synergy between our two organisations. We have known Abmart and its fantastic work for a long time and equally, they know how Arrayjet can be a significant value – add to their business, providing exceptional accuracy precision and quality they need to create and produce the vast libraries of monoclonal antibodies for its global customer base.  Moreover, we are delighted to work with them and help to extend our reach across Asia Pacific as well.”

 

The Abmart contract is the first deal concluded with APG-Bio also based in Shanghai who have been appointed Arrayjet’s distributor for the Asia Pacific market.

 

Arrayjet is supported by investment from the Archangels business angel syndicate and Scottish Enterprise

 

About Arrayjet

 

Arrayjet is a leading provider of innovative microarray solutions to researchers, drug development groups and diagnostic companies across 24 countries world-wide.  Offering a flexible, customer focussed approach with the provision of Arrayjet Advance™ microarray printing services in addition to a range of five scalable microarray printers, accessories & consumables.

 

Arrayjet’s microarray printing technology uses a unique, non-contact, inkjet printhead that offers unrivalled speed, reproducibility and precision to deliver high quality microarrays faster than any other technology.

 

www.arrayjet.com

 

Arrayjet is supported by investment from the Archangels business angel syndicate (www.archangelsonline.com) and Scottish Enterprise (www.scottish-enterprise.com).

 

 

About Abmart (Shanghai)

 

Abmart (Shanghai) was founded in 2007 with a goal to develop powerful yet accessible technologies to enable routine food and environment safety monitoring, protein diagnostics of health and disease as well as personalized disease treatment.

 

To achieve its goal, it focuses on creating revolutionary antibody products to enable fast, successful and cost-efficient discovery, detection and functional manipulation of proteins and chemical molecules.

 

www.ab-mart.com

Leave a Comment

Your email address will not be published. Required fields are marked *